The groundbreaking success of Viagra undeniably revolutionized the drug landscape, but placing funds in companies strongly reliant on unbranded versions presents a challenging picture. Despite early earnings were substantial, the end of patents and the emergence of here cheaper alternatives have weakened sales. Consequently, a thorough assessment o